Flatiron Health and Massive Bio join forces to improve cancer trial access
- Flatiron Health and Massive Bio have partnered to improve patient identification for clinical trials.
- The partnership aims to leverage AI and a U.S.-based database to identify patients near research sites.
- This collaboration highlights a commitment to advancing cancer treatment access and innovation.
In New York on April 7, 2025, Flatiron Health announced a strategic partnership with Massive Bio, a company renowned for its use of artificial intelligence in patient identification and recruitment for clinical trials. The collaboration aims to improve access to clinical trials for cancer patients by utilizing Massive Bio’s extensive U.S.-based database on a per-study basis. The goal is to identify patients who may be geographically close to participating sites but currently are not enrolled in clinical trials. This partnership is significant as it addresses disparities in clinical trial access and emphasizes patient-centric solutions in cancer treatment. Michael Bierl, Vice President of Clinical Research Partnerships at Flatiron Health, expressed enthusiasm about the partnership, highlighting the combined expertise to advance personalized treatments for cancer patients. The partnership will facilitate patient onboarding at Flatiron's research sites, thereby enabling potential trial enrollment through Flatiron's proprietary technology. Furthermore, Dr. Arturo Loaiza-Bonilla, Co-Founder of Massive Bio, stated that the mission is to ensure the right patients match the right trials promptly, regardless of their location, showcasing a commitment to improving access to vital clinical research. Selin Kurnaz, CEO of Massive Bio, emphasized the importance of advanced analytics in streamlining identification processes and reducing enrollment timelines, which may significantly enhance patient outcomes. This partnership marks a continuing effort by Flatiron Health to innovate within the realm of clinical trials, ensuring optimal patient matches and access to essential investigational therapies. The technological integration of Flatiron Health’s resources with Massive Bio’s capabilities is expected to empower care teams and accelerate the procedural aspects of trial enrollment. Overall, this cooperation signifies a proactive approach in fostering clinical research accessibility, thereby contributing beneficially to the healthcare ecosystem and addressing the pressing needs of cancer patients seeking innovative therapies.